Ordenar per
Keyphrases
Community-acquired Pneumonia
100%
Investigational Drugs
100%
Experimental Drugs
100%
New Antimicrobials
50%
Antibiotics
33%
Regulatory Agencies
33%
Safety Profile
33%
Non-inferiority
33%
Clinical Trials
16%
Bacterial Resistance
16%
New Drugs
16%
Etiology
16%
Assure
16%
Pseudomonas Aeruginosa (P. aeruginosa)
16%
Staphylococcus Aureus
16%
Phase I Clinical Trial
16%
Definitive Treatment
16%
Phase II Clinical Trial
16%
Phase III Clinical Trial
16%
Activity Profile
16%
Pneumococcus
16%
Therapeutic Regimen
16%
Acceptable Safety
16%
Common Infections
16%
Community Treatment
16%
Gepotidacin
16%
Lefamulin
16%
Solithromycin
16%
TP-271
16%
Delpazolid
16%
Delafloxacin
16%
Nafithromycin
16%
IDSA Guidelines
16%
Zabofloxacin
16%
Etiological Spectrum
16%
Omadacycline
16%
Nemonoxacin
16%
Radezolid
16%
Veterinary Science and Veterinary Medicine
Antibiotic Resistance
100%
Infectious Disease
100%
Staphylococcus aureus
100%
Pseudomonas aeruginosa
100%
Pneumococcus
100%
Pharmacology, Toxicology and Pharmaceutical Science
Community Acquired Pneumonia
100%
Clinical Trial
50%
Antibiotics
33%
Infectious Agent
16%
Infection
16%
Antiinfective Agent
16%
Pseudomonas aeruginosa
16%
Staphylococcus Aureus
16%
Radezolid
16%
Delafloxacin
16%
Omadacycline
16%
Lefamulin
16%
Nafithromycin
16%
Nemonoxacin
16%
Gepotidacin
16%
Zabofloxacin
16%
Delpazolid
16%
Solithromycin
16%
Antibiotic Resistance
16%
Streptococcus Pneumonia
16%